Graham Capital Management’s Nuvation Bio NUVB Stock Holding History

Graham Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$286K	Buy	+66,600	New	+$371K	0.01%	833
2025 Q4	–	Sell	-105,812	Closed	-$392K	–	1479
2025 Q3	$392K	Buy	+105,812	New	+$288K	0.01%	724
2025 Q2	–	Sell	-119,249	Closed	-$210K	–	1517
2025 Q1	$210K	Buy	+119,249	New	+$271K	﹤0.01%	1122
2023 Q1	–	Sell	-31,673	Closed	-$60.8K	–	1249
2022 Q4	$60.8K	Buy	+31,673	New	+$64.1K	﹤0.01%	1001
2022 Q1	–	Sell	-33,816	Closed	-$287K	–	985
2021 Q4	$287K	Buy	+33,816	New	+$311K	0.01%	341

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Graham Capital Management's NUVB Position: Q1 2026 in Review

Graham Capital Management opened a new position in Nuvation Bio (NUVB) in Q1 2026: 66,600 shares worth $286K. The stake represents 0.01% of the portfolio and ranks #833 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in NUVB as recently as Q3 2025.

Graham Capital Management first reported a position in NUVB in Q4 2021 and has held it in 5 quarters since. The position peaked at $392K in Q3 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

Graham Capital Management held 66,600 shares of Nuvation Bio worth $286K as of Q1 2026.
Nuvation Bio was a new Graham Capital Management position in Q1 2026.
Nuvation Bio made up 0.01% of Graham Capital Management's portfolio in Q1 2026, its #833 holding.
Graham Capital Management first reported a position in Nuvation Bio in Q4 2021 and has held it in 5 quarters since.
Graham Capital Management's Nuvation Bio position peaked at $392K in Q3 2025.
231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.